Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
Nanox (NASDAQ: NNOX) reported Q3 2024 financial results with revenue of $3.0 million, up from $2.5 million in Q3 2023. The company posted a net loss of $13.6 million, improved from $21.4 million loss year-over-year. Teleradiology services generated $2.6 million in revenue with a 13% gross profit margin. The company continues expanding US sales teams and deploying units globally, while progressing with FDA applications for full body scanning and CE Mark designation. Cash position stands at $57.1 million as of September 30, 2024, down from $82.8 million at end of 2023.
Nanox (NASDAQ: NNOX) has announced it will release its third quarter 2024 financial results before market open on Thursday, November 21, 2024. The company will host a conference call at 8:30 a.m. ET, featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, to discuss the results and provide a business update. Interested parties can access the call through registration and a live webcast, which will be available on the company's Investor Relations website.
Nanox AI, a subsidiary of NANO-X IMAGING (NNOX), has received a Special Mention in TIME's Best Inventions of 2024 list for its innovative medical imaging analytics solutions. The company's FDA-cleared AI technology analyzes routine CT scans to detect early signs of chronic conditions in cardiac, liver, and bone health. Their solutions include HealthCCSng for coronary artery calcification measurement, HealthOST for spine analysis, and HealthFLD for liver evaluation, all aimed at identifying previously undetected asymptomatic conditions to promote preventive care management.
Nanox (Nasdaq: NNOX), an innovative medical imaging technology company, has announced its participation in the Cantor Fitzgerald Global Healthcare Conference in September 2024. This investor conference provides an opportunity for Nanox management to showcase their cutting-edge medical imaging solutions and engage with potential investors and industry professionals.
The participation in this prestigious healthcare conference underscores Nanox's commitment to expanding its market presence and fostering relationships within the investment community. As a company at the forefront of medical imaging technology, Nanox's attendance at the conference may offer valuable insights into their latest developments, market strategies, and future growth prospects.
Nanox (NASDAQ: NNOX) has received FDA 510(k) clearance for HealthCCSng V2.0, an upgraded version of its AI-powered cardiac solution. This marks the second FDA clearance for the HealthCCSng product line. The new version introduces:
1. A 'zero calcium' category for coronary artery calcium (CAC) assessment
2. Numerical calcium scoring alongside CAC detection categories
3. Customizable CAC category configurations
HealthCCSng V2.0 analyzes non-gated, non-contrast CT scans to automatically measure CAC in patients aged 30-85. It aims to leverage routine CT scans for early detection of coronary artery disease risk. The solution has already been integrated into several healthcare systems, improving patient risk assessment and driving revenue to cardiology departments.
Nanox (NASDAQ: NNOX) announced Q2 2024 financial results and provided a business update. Key highlights include:
- Revenue of $2.7 million, up from $2.6 million in Q2 2023
- Net loss of $13.6 million, decreased from $17.4 million in Q2 2023
- Submitted new 510k application to FDA for expanded Nanox.ARC indications
- Advanced US deployment of Nanox.ARC, with systems in seven states
- Nanox.AI received FDA 510K clearance for HealthCCSng V2.0
The company reported a gross loss of $2.9 million (106% margin) on a GAAP basis. Non-GAAP gross loss was $0.2 million (9% margin). Nanox ended the quarter with $64.2 million in cash, cash equivalents, restricted deposits, and marketable securities.
Nanox (NASDAQ: NNOX), an innovative medical imaging technology company, has announced its plans to report second quarter 2024 financial results on August 20, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Erez Meltzer, CEO and Acting Chairman, and Ran Daniel, CFO, will lead the call. Interested parties can register for the conference call and access the live webcast through links provided by the company. An archived replay of the webcast will be available on the Nanox website after the call concludes.
Nanox.AI's Cardiac Solution (HealthCCSng) was featured in multiple scientific presentations at the 2024 SCCT Annual Meeting, showcasing its potential in early detection and preventive care of cardiovascular disease. Key findings include:
1. Brigham & Women's Hospital study: HealthCCSng detected Coronary Artery Calcification (CAC) in over 50% of immune-mediated inflammatory disease patients, associated with increased mortality and cardiovascular risks.
2. Corewell Health implementation: HealthCCSng analyzed 32,650 chest CT scans, identifying 3,721 new patients with medium/high CAC, a 13-fold increase from previous years.
3. Jefferson Einstein Hospital study: HealthCCSng identified 757 patients with high CAC levels, leading to 308 follow-up visits and generating up to $130,000 in revenue.
These studies demonstrate HealthCCSng's clinical and economic benefits in improving cardiovascular risk assessment and patient care.
Nanox Imaging (Nasdaq: NNOX) announced that data from five studies supporting its AI Cardiac Solution, HealthCCSng, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT) from July 18-21 in Washington, D.C.
These studies are by institutions including Brigham & Women’s Hospital, Einstein Jefferson Medical Center, Corewell Health, Massachusetts General Hospital, and Beilinson Medical Center. HealthCCSng uses routine chest CT scans to quantify coronary artery calcium (CAC) levels, a strong predictor of future cardiac events. Patients with high CAC are up to 6x more likely to suffer from cardiac events.
Key presentations include: 'The Frequency, Prevalence, And Outcomes of Incidentally Detected Coronary Artery Calcium Using AI Analysis' by Brittany Weber (July 20, 10:30 AM), and 'Optimizing Preventive Cardiology: Harnessing AI for Early Detection of CAD' by Dr. Chiduzie Madubata (July 19, 9:30 AM - 10:15 AM).
Nano-X Imaging announced the integration of AI solutions into its Second Opinions platform, enhancing its teleradiology services. This advancement leverages deep-learning AI from Nanox.AI to analyze chest and abdominal CT scans, aiming to detect chronic conditions early. The platform, managed by USARAD Holdings, now includes FDA-cleared AI tools: HealthCCSng for coronary artery disease, HealthOST for osteoporosis risk, and HealthFLD for fatty liver disease. These AI findings are vetted by physicians and integrated into patient reports.